Clinical studies have shown that circulating irisin levels are lower in patients with either stable coronary artery disease or MI than in healthy controls[32] and that lower irisin levels are an independent predictor of coronary artery disease severity.[33] We demonstrated that irisin pretreatment increased the cardiac homing of intravenously injected ADSCs in post MI/R mice and rats by tracking ADSCs with CM‐DiI staining or genetic GFP and tdTomato labeling. This evidence concerns the gene FNDC5 and myocardial infarction.